|
Back to Home » December 2019 News » Additional Analyses From Phase 3 study With Doptelet ® (avatrombopag) for the treatment of Chronic Immune Thrombocytopenia Provides Evidence of Long-term Response Rates |
Additional Analyses From Phase 3 study With Doptelet ® (avatrombopag) for the treatment of Chronic Immune Thrombocytopenia Provides Evidence of Long-term Response Rates |
December 09, 2019
STOCKHOLM, Dec. 9, 2019 /PRNewswire/ -- Dova Pharmaceuticals, a wholly owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi™), presented additional analyses from the phase 3 study - core and extension phase - with avatrombopag (AVA) for the treatment of immune thrombocytopenia...
Source URL: https://www.prnewswire.com:443/news-releases/additional-analyses-from-phase-3-study-with-doptelet--avatrombopag-for-the-treatment-of-chronic-immune-thrombocytopenia-provides-evidence-of-long-term-response-rates-300971110.html
|
|
|
|
